A5011537298- Hemophilia Treatment and Research
- Platelet Disorders and Treatments
- Cancer-related gene regulation
- Hemostasis and retained surgical items
- Blood Coagulation and Thrombosis Mechanisms
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Medical and Biological Sciences
- Healthcare Systems and Public Health
- Employee Welfare and Language Studies
- Pregnancy and preeclampsia studies
- Long-Term Effects of COVID-19
- Intracerebral and Subarachnoid Hemorrhage Research
- Vascular Anomalies and Treatments
- Galectins and Cancer Biology
- Lipid metabolism and disorders
- Blood groups and transfusion
- Renal and Vascular Pathologies
- Hepatitis C virus research
- Systemic Sclerosis and Related Diseases
- COVID-19 Clinical Research Studies
- Heparin-Induced Thrombocytopenia and Thrombosis
- Vanadium and Halogenation Chemistry
- Neurological Disorders and Treatments
- Liver Disease and Transplantation
Samara State Medical University
2015-2020
Ministry of Health of the Russian Federation
2015-2019
Г
Relevance. The development of a new recombinant blood coagulation factor VIII preparation is promising step towards optimizing the treatment hemophilia A. An introduction medication into clinical practice precedes trials to evaluate efficacy and safety. Materials methods. safety domestic B-domain deleted (FVIII) (moroctocog alfa, Octofactor®, JSC “GENERIUM”) were studied in preventive 31 patients aged 21 52 years with severe haemophilia Octofactor was administered doses 40 ± 5 IU/kg 3 times...
Результаты многоцентрового, проспективного, открытого, неконтролируемого исследования эффективности и безопасности препарата Иннонафактор у пациентов в возрасте 12 лет старше с тяжелой среднетяжелой гемофилией В
Relevance . In accordance with the guidelines on clinical investigation of clotting factor VIII products European Medicines Agency and pharmacovigilance Eurasian Economic Union, after registration a new drug, it is recommended to study its efficacy safety large population patients in standard medical practice clarify identify data. Materials methods prospective, multicenter, open-label, uncontrolled observational study, domestic recombinant B-domain deleted blood FVIII (FVIII) (moroctocog...
Introduction. Frequent bleeding with hemophilia significantly worsens the quality of life patients. The pathogenesis hemorrhage in has not been studied enough, especially at vascular level, so it is necessary to study microcirculation this disease. purpose assess mechanisms regulation blood tissue perfusion and adaptive reserves system patients hemophilia. Materials methods. Total was assessed by laser Doppler flowmetry 44 A between ages 14 20 years. Severe form disease 59 % patients,...
The aim of the study was to evaluate efficacy, safety and pharmacokinetics nonacog alfa (Innonafactor) in children aged 2 12 years with hemophilia B. Materials methods: 15 patients (7.7±2.5 ) were included an open, multicenter, prospective, non-comparative clinical trial, whom 6 3 years. efficacy drug assessed against background introduction 45±10 IU/kg times a week interval 72–96 hours, by frequency nature adverse reactions. Results: 5 (22%) spontaneous 18 (78%) post-traumatic bleedings...
The article shows the possible use of sulodexidi in a patient with primary infertility unknown origin associated an excess plasminogen activator type 1 inhibitor. This method illustrates possibility pregnancy when taking at stage pregravidar preparation woman hypofibrinolysis.
Введение. Новая коронавирусная инфекция COVID-19 представляет повышенную опасность инфицирования у медицинских работников. Цель исследования: показать возможность применения дипиридамола работников в комплексе мер первичной профилактики новой коронавирусной инфекции COVID-19. Материалы и методы. Наблюдались 33 работника: 14 человек принимали дипиридамол дополнение к стандартным методам профилактики; 19 человек, не принимавшие дипиридамол, составили группу сравнения. Результаты. Несмотря на...
Currently, the main method of treatment for hemophilia A is replacement therapy with drugs blood coagulation factors VIII (FVIII). As a result development new production technologies, recombinant FVIII are increasingly used A. The justification use in pediatric clinical practice requires careful preparation and research studies their efficacy safety. aim this study was to evaluate efficacy, safety pharmacokinetics (PK) domestic B-domain deleted factor Moroctocog alpha (Octofactor, GENERIUM...
The article shows the role of definition antiplatelet antibodies in patients with idiopathic thrombocytopenic purpura and those drug thrombocytopenia to decide on choice tactics how treat disease determine prognosis. It is shown that this method research not determinative chronic different genesis.